Bruker Corporation (BRKR) Financial Statements
Historical financial data — 39 statements covering FY2016–FY2025
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segme...
Bruker Corporation's revenue increased 2.1% year over year, from $3.37B to $3.44B.
Net income decreased 107.6% over the same period, from $113.1M to $-8.6M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 113% in total.
Total debt decreased by 10.8% to $1.87B.
The debt-to-equity ratio stands at 0.76, indicating a moderate leverage profile.
Operating cash flow declined 46.6% to $134.1M.
Bruker Corporation maintains a negative net profit margin of -0.3%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $1.52B+105.0% | $58.5M | $737.4M | $112.9M | $22.9M | $5.90B | $2.16B | $1.79B |
| Q3 FY2024 | $864.4M-43.2% | $40.9M | $418.8M | $68.1M | $38.4M | $6.11B | $2.30B | $1.81B |
| Q4 FY2024 | $979.6M+13.3% | $13.7M | $493.3M | $72.1M | $190.0M | $5.81B | $2.09B | $1.78B |
| Q1 FY2025 | $801.4M-18.2% | $17.4M | $391.2M | $31.8M | $65.0M | $5.93B | $2.11B | $1.83B |
| Q2 FY2025 | $797.4M-0.5% | $7.6M | $357.9M | $11.9M | $-127.5M | $6.34B | $2.44B | $1.82B |
| Q3 FY2025 | $860.5M+7.9% | $-59.6M | $379.4M | $-51.8M | $-33.2M | $6.43B | $2.01B | $2.43B |
| Q4 FY2025 | $977.2M+13.6% | $26.0M | $449.2M | $76.3M | $229.8M | $6.24B | $1.87B | $2.46B |
| Q1 FY2026 | $823.4M-15.7% | $14.4M | $379.8M | $10.2M | $71.2M | $6.13B | $1.67B | $2.47B |
Balance Sheet Summary (Latest Period)
Bruker Corporation (BRKR) Financial Statements & Revenue History
Bruker Corporation (BRKR) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry trading at $62.00 with a market capitalization of $9. This page provides 39 historical financial statements for Bruker Corporation, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Bruker Corporation reported revenue of $3.4 billion, representing 2.1% year-over-year growth. The net profit margin of -0.3% indicates the company is currently unprofitable. The debt-to-equity ratio of 0.76 reflects moderate leverage.
BRKR Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Bruker Corporation's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BRKR is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BRKR's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Bruker Corporation converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BRKR's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BRKR Financial Data
Investors use Bruker Corporation's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BRKR's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BRKR's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BRKR's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Bruker Corporation's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BRKR trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.